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Definition  
Aa acute coronary syndrome (ACS)  has evolved as a useful 
operational term that refers to a spectrum of conditions 
compatible with acute myocardial ischemia and/or infarction (MI) 
that are usually due to an abrupt reduction in coronary blood 
flow ranging clinically from those for ST-segment elevation 
myocardial infarction (STEMI) to presentations found in non–ST-
segment elevation myocardial infarction (NSTEMI) or in unstable 
angina (UA). 
Most patients with STEMI develop QMI, and a few  develop 
NQMI. Most  of those without ST-elevation develop NQMI and 
only a few may develop QMI.  
The ACS associated with high healthcare costs, frequent 
recurrences and hospitalizations, and high risks of sudden death 
and short-term mortality 
 emedicine.medscape.com/article/1910735-overview content.onlinejacc.org/article.aspx?articleid=1910086 
Definition 
(Unstable Angina )  
• UA is defined as myocardial ischemia at rest or minimal 
exertion in the absence of cardiomyocyte necrosis. 
• Among patients presenting with suspected NSTE-ACS, the 
introduction of high-sensitivity cardiac troponin 
measurements in place of standard troponin assays resulted in 
an increase in the detection of MI  and a reciprocal decrease in 
the diagnosis of UA. 
• Compared with NSTEMI patients, individuals with UA do not 
experience myocardial necrosis, have a substantially lower risk 
of death and appear to derive less benefit from intensified 
antiplatelet therapy as well as early invasive strategy. 
eurheartj.oxfordjournals.org/content/37/3/267   
Definition 
(Definitions of Myocardial Infarction)  
• Universal: MI defines cardiomyocyte necrosis in a clinical 
setting consistent with acute myocardial ischemia. 
• My: Acute myocardial infarction is a disease or a clinical 
syndrome accompanying other diseases, which is represented 
by acute coronarogenous aseptic inflammation of the part of a 
heart wall, and clinically correlates with stress reactions of 
body control systems and is determined by the extent, 
localization, nature, and stage of structural transformations in 
the infarction zone, as well as circulation changes, and their 
consequences. 
eurheartj.oxfordjournals.org/content/37/3/267 im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf  
Epidemiology   
(Acute Coronary Syndrome around the World) 
eurheartj.oxfordjournals.org/content/33/20/2569 
• Worldwide, coronary artery disease (CAD) is the single most 
frequent cause of death.  
• Over seven million people every year die from CAD, 
accounting for 12.8% of all deaths. 
• Every sixth man and every seventh woman in Europe will die 
from myocardial infarction.  
• The incidence of hospital admissions for myocardial infarction 
varies among countries. 
• The most comprehensive STEMI registry is probably in 
Sweden, where the incidence is 66 STEMI/100 000/year.   
Epidemiology   
(Acute Coronary Syndrome in the Spanish Population) 
revespcardiol.org/en/epidemiology-of-acute-coronary-syndromes/articulo/90202863/ 
Number of acute coronary syndrome cases, trend from 2005 to 
2049 by sex and age group in the Spanish population. ACS, acute 
coronary syndromes. 
Epidemiology   
(Troponin and Diagnosis of ST-elevated and non-ST-
elevated Acute Myocardial Infarction) 
nature.com/nrcardio/journal/v8/n3/images/nrcardio.2010.199-f2.jpg 
Quality of a diagnosis depends strictly from diagnostic 
procedures 
Risk Factors 
mayoclinic.org/ image.slidesharecdn.com/asimnstemi-final-140204114442-phpapp01/95/acute-coronary-syndrome-nstemi-7-638.jpg?cb=1400815933 
The risk factors 
for an ACS are 
the same as 
those for other 
types of clinical 
atherosclerosis 
including heart 
disease. 
Etiology 
content.onlinejacc.org/article.aspx?articleid=1910086 
• The hallmark of an ACS is the sudden imbalance between 
myocardial oxygen consumption (MVO2) and demand, which is 
usually the result of coronary artery obstruction.  
• The imbalance may also be caused by other conditions: 
excessive myocardial oxygen demand in the setting of a stable 
flow-limiting lesion; acute coronary insufficiency due to other 
causes (e.g., vasospastic [Prinzmetal] angina, coronary 
embolism, coronary arteritis); noncoronary causes (e.g., 
hypotension, severe anemia, hypertension, tachycardia, 
hypertrophic cardiomyopathy, severe aortic stenosis); 
nonischemic myocardial injury (e.g., myocarditis, cardiac 
contusion, cardiotoxic drugs); and multifactorial causes (e.g., 
stress [Takotsubo] cardiomyopathy, pulmonary embolism, 
severe heart failure [HF], sepsis). 
Mechanisms   
(In Reversible and Irreversible Ischemia Terms )     
• UA develops, until 
local coronary 
circulation 
disturbances cross 
the time of reversible 
ischemia. 
• MI develops, when 
local coronary 
circulation 
disturbances cross 
the time threshold 
and make the 
ischemia irreversible.   
 medicinembbs.blogspot.com/2011/06/what-is-difference-between-nstemi-and.html 
Dx - abbreviation for diagnosis. 
 
Mechanisms   
(Key Moments)     
• Mechanisms of an ACS were selected by evolution and  
consist at systemic and local levels. 
• These mechanisms are aimed at providing most favourable of 
possible the ACS courses. 
• Their disturbances build  complications of the ACS.  
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Systemic Level: 1)     
• The response of body systems to an ACS is realized through 
stress and manifests itself as brain mediated sympathetic 
activation and increased functional activity of a hypothalamo-
pituitary an adrenal systems with the change of functions of 
all target organs.  
• For a favourable course and outcome of the ACS, all other 
conditions being equal, an adequate organization of stress 
(eustress) becomes of primary importance.  
• For STEMI leukocyte reactions are important for the further 
development of the process:  
• These reactions are triggered by the ejection of leukocytes 
from the depot to the systemic blood flow.   
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Systemic Level: 2)     
• Since the depot mainly contains neutrophils, leukocytosis 
appears as the shift in cell count, neutrophils are activated 
and migrate to the infarction zone by positive chemotaxis. 
Infarction zone products getting in the blood flow play the 
role of attractants for them.  
• The activation of neutrophils appears as hyperenzymemia, 
higher contents of eicosanoids, leukotrienes in particular, 
protein carbohydrate complexes, and other biologically 
active agents.  
• Stress is changing as the process develops and leukocytosis 
declines with the leukogram changes. Granulocyte counts 
decrease, and their functional activity is suppressed, while 
agranulocyte counts and their activity increase.   
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Systemic Level: 3)     
• The structural change of the leukogram is the result of 
controlling effects of infarction zone products getting in 
the blood flow: neutrophil decay products from the 
infarction zone are repellents for neutrophils and 
attractants for agranulocytes.  
• As result an enzyme level in blood falls, while the proteins 
and protein-carbohydrate complexes content grows. 
• These are the systemic manifestations of an inflammation 
process in the infarction zone.   
• With the termination of an acute myocardial infarction 
phase, regulation problems disappear and not a trace 
remains of the stress.   
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Local Level)     
• The local level is the 
heart.  
• The components of a 
pathologic process 
are not only changes 
in the infarction zone 
and recovery of 
heart shape and size 
but also adaptive 
changes of heart 
biomechanics. 
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf amjmedsci.org/ 
The top panels show the infarction zone and the 
bottom panels show the border (periinfarction) 
zone 
Mechanisms   
(Infarction Zone: 1)     
• All that happens is inflammation: special, aseptic, alterative 
but still inflammation.  
• The first one is ischemia, reversible myocardial changes 
(NSTEMI).  
• The transfer to irreversible changes (STEMI) marks the onset 
of necrosis, and with the transfer from ischemic changes in 
the infarction zone to the necrotic ones, the inflammation 
starts in accordance with its traditional scheme.  
• The necrotized myocardium undergoes destruction, and decay 
products are removed through the peri-infarction zone.  
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Infarction Zone: 2)     
• The necrotized myocardium is specifically destroyed by 
neutrophil getting by chemotaxis from blood into the 
infarction zone and produsing cathepsins. Their migration rate 
is rather high, about 2-4 mm per hour and even the largest 
possible infarction is infiltrated by neutrophils in 6 hours at 
the most.  
• At the same time, fibroblast precursors enter the infarction 
zone and the recovery process begins.  
• It is impossible to separate necrotic and reparative processes, 
to look at them as the individual ones. They are synchronized 
and interconnected not only at the level of the infarction zone 
itself but also at the systemic blood level.  
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Infarction Zone: 3)     
• The result of a natural inflammation course in the infarction 
zone is the formation of a full-fledged scar in the place of 
necrosis .  
• Maturation of a granulation tissue results in its consolidation 
followed by a decrease in infarction zone sizes. Depending on 
conditions, they can decrease by 25% or more.  
• I should remind those who want to strongly intervene in the 
infarction zone that the phenomena occurring there 
(inflammation, compensatory and adaptive responses) are 
protective reactions originated as the result of evolution.  
• We may intervene in these processes but carefully. 
 
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Periinfarction Zone)     
• Systemic mechanisms and the infarction zone are 
interconnected through the periinfarction zone, first of all, 
through its microcirculatory bed.  
• Wastes from the infarction zone are removed through it, and 
the products necessary for reparative processes enter there 
the same way.  
• The larger the infarction–periinfarction zone interface, the 
better the mutual effect of the infarction zone and systemic 
control.  
• The peri-infarction zone cannot be smaller than that required 
for uncomplicated healing of the infarction. 
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Heart Shape and Size)     
• In the case of infarction, a part of a myocardium becomes 
disabled and its functions should be compensated.  
• Hypertrophy of an intact myocardium develops.  
• Healing of the infarction zone accompanied with the 
consolidation of scar leads to a decrease in its size.  
• The heart shape is remodeled in such a way that its anatomic 
proportions are restored to favor its pumping functions.  
• In the best case, the traces of infarction are difficult to reveal, 
even after thorough investigations. 
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Complications: Frequency and Immediate Cause)     
• Acute myocardial infarction is a complex and vulnerable 
process.  
• In the most optimistic estimations, its complications are 
observed somewhere in a quarter of cases, if it is diagnosed 
and treated correctly.  
• The immediate cause of complications is inadequate stress or 
distress.  
• Have little patience, and we would see how distress is realized 
as complications. 
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Complications: Standard Mechanism)     
• The cause of complications is (hyper reactive, hypo reactive or 
intermittent) distress.  
• The mechanism of complications, irrespective of a distress 
type, is always the same, viz. desynchronization of necrotic 
and reparative processes. 
• Desynchronization of necrosis and reparation leads to the loss 
of heart wall strength in the infarction zone with cardiac 
aneurysm or heart rupture outcomes.   
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Complications: Hyperreactive Distress)     
• The result of hyperreactive distress is in intensive and rapid 
migration of polynuclears to the infarction zone with 
acceleration of necrosis and destruction of infarcted 
myocardium  and lag behind of reparative processes. 
• There is the desynchronization.  
• Fast destruction of myocardium in the infarction zone has one 
more consequence, viz. high concentration gradients of all 
products formed in it along the boundary with the peri-infarct 
zone with the electronic instability of a heart and as a result, 
arrhythmia.   
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Complications: Hyporeactive Distress)     
• In this the case everything develops slowly.  
• Systemic reactions are sluggish or are absent at all.  
• Thus, there are problems with the infiltration of polynuclears 
to the infarction zone and the necrotic phase is slow, which 
leads to the delay of reparative processes and their slow 
development.  
• There is the desynchronization again. 
• Hypo reactive distress with a sluggish disease pattern 
determines large sizes of aneurysm and as a rule, heart 
rupture occurs in the thinnest area of aneurysm. 
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf 
Mechanisms   
(Complications: Intermittent Distress)     
Intermittent distress 
means superposition 
of the above 
mechanisms by the 
formula 'out of the 
frying-pan into the 
fire‘ and everything 
becomes much more 
dangerous. 
 
im.medicine.karazin.ua//downloads/presentations/Yabluchanskiy_Infarction_Strategy.pdf studyblue.com/#flashcard/view/15784631 
Classification 
(International Classification of Diseases (ICD)) 
icd10coded.com/cm/ch9/I20-I25/ 
Chapter IX 
Diseases of the circulatory system 
(I00-I99)  
I20-I25 Ischemic heart diseases 
I20.0 Unstable angina: Angina (crescendo, de novo effort, worsening 
effort), Intermediate coronary syndrome, Preinfarction syndrome   
I21 ST elevation (STEMI) and non-ST elevation (NSTEMI) 
myocardial infarction 
122 Subsequent ST elevation (STEMI) and non-ST elevation 
(NSTEMI) myocardial infarction 
123 Certain current complications following ST elevation (STEMI) 
and non-ST elevation (NSTEMI) myocardial infarction (within the 
28 day period) 
124 Other acute ischemic heart diseases 
Classification 
(Acute Coronary Syndromes Types) 
medicinembbs.blogspot.com/2011/06/what-is-difference-between-nstemi-and.html hrombosisadviser.com/en/acs/a-leading-cause-of-mortality 
  
• STEMI - occlusive thrombus - ST elevation (and Q waves) - 
Cardiac Enzyme elevation - Fibrinolytics beneficial 
• NSTEMI - non-occlusive thrombus - NO ST/Q - Cardiac Enzyme 
elevation present - Fibrinolytics not beneficial 
• UA - non-occlusive thrombus - NO ST/Q - Cardiac Enzyme 
elevation absent - Fibrinolytics not beneficial 
 
Classification 
(Myocardial Infarction) 
metalyse.com/myocardial_infarction/types.html 
  
• Anatomic perspective: transmural, nontransmural 
(subendocardial, subepicardial) 
• Localization:  anterior, lateral, posterior, septal, inferior, right 
ventricle   
• Clinical periodization: acutest (UA), acute (predominance  of 
necrotic processes), subacute (predominance  of reparative 
processes), postinfarction (consolidation of postinfarction 
scar) 
• Course: noncomplicated, complicated (hyperreactive, 
hyporeactive) 
 
Clinical Investigation  
(Symptoms) 
• The cardinal symptom is chest pain, experienced as tightness 
around the chest and radiating to the left arm and the left angle 
of the jaw.  
• This may be associated with diaphoresis (sweating), nausea and 
vomiting, as well as shortness of breath.  
• In many cases, the sensation is "atypical", with pain experienced 
in different ways or even being completely absent (which is 
more likely in female patients and those with diabetes).  
• Some may report arrhythmia, anxiety or a sense of impending 
doom (angor animi) and a feeling of being acutely ill. 
• The description of the chest discomfort as a pressure has little 
utility in aiding a diagnosis as it is not specific for ACS. 
en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms 
Clinical Investigation  
(Common Locations and Patterns of  Chest Pain) 
s3.amazonaws.com/classconnection/12/flashcards/9384012/png/angina-153389544C30E11EA69.png eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf 
The characteristics of discomfort-related to chest pain may be divided into four categories: 
location, character, duration and relationship to exertion and other exacerbating or relieving 
factors. The discomfort caused by myocardial ischemia is usually located in the chest, near 
the sternum, but may be felt anywhere from the epigastrium to the lower jaw or teeth, 
between the shoulder blades or in either arm to the wrist and fingers. 
Clinical Investigation  
(Distribution of ACS) 
quizlet.com/15191588/study-2-flash-cards/ 
Clinical Investigation  
(History) 
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
• The history should include any current symptoms and a 
complete inventory of comorbid conditions.  
• An inventory of cardiac risk factors, and a complete family 
history are essential components.  
• The history should also include information about the 
character and location of discomfort, radiation of discomfort, 
associated symptoms, and precipitating, exacerbating, or 
alleviating factors.  
• The importance of the family history should not be 
underestimated.  
• A detailed assessment, particularly of first-degree relatives for 
the presence of coronary artery disease and age of diagnosis 
is imperative when evaluating a patient's risk factor profile. 
Clinical Investigation  
(Physical Examination) 
clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/coronary-artery-disease/ 
• The results of the physical examination of a patient may be 
entirely normal.  
• The presence of multiple risk factors or atherosclerosis 
symptoms increases the likelihood that a chest pain is related to 
myocardial ischemia.  
• Evaluation should include measurements of blood pressure, the 
ankle-brachial index, cardiac and carotid arteries auscultation 
for bruits.  
• Examination of the chest wall, neck, and shoulders for 
deformities and tenderness may be helpful in diagnosing 
musculoskeletal chest discomfort.  
• The physical examination may help identify comorbid 
conditions that impact therapeutic risk and decision making.  
Clinical Investigation  
(Myocardial Infarction versus Stable Angina 
Comparison Chart) 
diffen.com/difference/Myocardial_Infarction_vs_Stable_Angina 
Symptoms Myocardial Infarction Stable Angina 
Occurrence of 
pain 
Occurs at any time Occurs due to physical  or 
emotional stress 
Modality of 
pain 
With damage to the heart and 
usually described as severe, 
steady, and crushing  
With no damage to the 
heart   
Outcome May be fatal Usually not fatal 
Relieving 
factors of pain 
Symptoms persists after 15 min. 
and not relieved by rest or nitro  
Symptoms relieved by rest 
or nitro within 10-15 min.  
Duration of 
pain 
Usually lasts for more than 15 
min. 
Usually for less than 15 min.; 
discomfort is transient, 
lasting 3-5 min. 
Serum cardiac 
marker 
Present Not present 
Clinical Investigation  
(Sequence of Changes in evolving MI) 
nottingham.ac.uk/nursing/practice/resources/cardiology/acs/changes.php 
Clinical Investigation  
(ECG’ Localizing of Myocardial Injury) 
ems.sluhn.org/images/stemi_alert_opt.png 
Clinical Investigation  
(Complications) 
• Complications may occur immediately following the heart 
attack (in the acute phase), or may need time to develop (a 
chronic problem).  
• Acute complications may include heart failure if the 
damaged heart is no longer able to pump blood adequately 
around the body; aneurysm of the left ventricle 
myocardium; ventricular septal rupture or free wall 
rupture; mitral regurgitation, in particular if the infarction 
causes dysfunction of the papillary muscle; Dressler's 
syndrome; and abnormal heart rhythms, such as ventricular 
fibrillation, ventricular tachycardia, atrial fibrillation, 
and heart block.  
• Longer-term complications include heart failure, atrial 
fibrillation, and an increased risk of a second MI. 
en.wikipedia.org/wiki/Myocardial_infarction 
Clinical Investigation  
(Outcome of ACS) 
quizlet.com/15191588/study-2-flash-cards/ 
Diagnosis 
  
• Blood tests: cardiac 
biomarkers; WBC; 
cholesterol and C-
reactive protein 
levels. 
• Electrocardiogram 
(ECG). 
• B-mode, Doppler and 
intravascular 
ultrasound. 
• Vascular 
catheterization and 
angiogram. 
• Other imaging tests. 
en.wikipedia.org/wiki/Coronary_artery_disease#Diagnosis afghanheart.files.wordpress.com/2013/04/troponins.jpg 
Diagnosis 
(Initial Assessment of Patients with Suspected ACS)  
 eurheartj.oxfordjournals.org/content/37/3/267 
Diagnosis 
(Criteria for Diagnosis of MI)  
A combination of criteria is required to meet the diagnosis 
of MI, namely the detection of an increase and/or decrease 
of a cardiac biomarker, preferably high-sensitivity cardiac 
troponin, with at least one value above the 99th percentile 
of the upper reference limit and at least one of the 
following: symptoms of ischemia; new or presumed new 
significant ST-T wave changes or left bundle branch block on 
12-lead ECG; development of pathological Q waves on ECG; 
imaging evidence of new or presumed new loss of viable 
myocardium or regional wall motion abnormality; 
intracoronary thrombus detected on angiography or 
autopsy. 
eurheartj.oxfordjournals.org/content/37/3/267 
Diagnosis 
(Cardiac Biomarkers)  
Biomarkers related to necrotic processes in myocardial infarction zone 
quizlet.com/15191588/study-2-flash-cards/ 
Diagnosis 
(Indications for Measurement of Troponins)  
• Cardiac troponin I and T have displaced myoglobin and creatine kinase-MB 
as the preferred markers of myocardial injury. 
• Serum levels increase within 3-12 hours from the onset of chest pain, peak 
at 24-48 hours, and return to baseline over 5-14 days. 
• Troponin levels may not be detectable for six hours after the onset of 
myocardial cell injury. The most sensitive early marker for myocardial 
infarction is myoglobin. 
• Troponin levels should be measured at presentation and again 10-12 hours 
after the onset of symptoms. When there is uncertainty regarding the time 
of symptom onset, troponin should be measured at twelve hours after the 
presentation. 
• The risk of death from an ACS is directly related to troponin level and 
patients with no detectable troponins have a good short-term prognosis. 
• Elevated troponin levels can occur in patients without an ACS and are 
associated with adverse outcomes in many other clinical situations, 
including congestive heart failure, sepsis, acute pulmonary embolism and 
chronic kidney disease. Other cardiac causes include myocarditis and aortic 
dissection. 
 patient.info/doctor/cardiac-enzymes-and-markers-for-myocardial-infarction 
Diagnosis 
(Electrocardiogram)  
health-tutor.com/simple-cardiac-ischemia-ecg.html 
There are ST and T changes in leads II, III, aVF (solid red circles) – 
it is a suspicion of ischemia of the inferior myocardial wall. 
Similar change is outlined in the lead V6 (dashed circle). 
Diagnosis 
(Electrocardiogram)  
healio.com/cardiology/learn-the-heart/blogs/stemi-mi-ecg-pattern 
Inferior STEMI in acutest phase 
Diagnosis 
(Electrocardiogram)  
healio.com/cardiology/learn-the-heart/blogs/stemi-mi-ecg-pattern 
An  inferior STEMI with a right bundle branch block on the ECG. 
Еhe reciprocal depression in lead I and aVL. 
Diagnosis 
(Criteria of Differentiation Noncomplicated and  
Complicated MI)  
meteopathy.com/zdorovye-i-bolezn/my-myocardial-infarction-phylosophy/2/ 
Criterion Type of acute myocardial infarction 
Noncomplicated 
with eureactive 
stress 
Complicated with 
hyperreactive 
distress 
Complicated with 
hyporeactive 
distress 
Blood leukocytes, E 9 1/l.: 1st day results and further 
dynamics 
7-11, rapid 
decrease 
>11, slow 
decrease 
<7, increase, then 
slow decrease 
Shift of leukocytes, arb. units: 1st day results and 
further dynamics 
3.0-6.5, rapid 
decrease 
>6.5, slow 
decrease 
<3.0, increase, 
then slow 
decrease 
Time of maximum activity of enzymes, hrs 16-22, rapid 
decrease 
>16, slow 
decrease 
>22, slow 
decrease 
Initial period of protein-carbohydrate complex 
growth, days 
1-2 >2 >2 
Period of reaching maximum protein-carbohydrate 
complex concentrations, days 
4-5 >5 >5 
Interval between maxima of enzymes and protein-
carbohydrate complexes, days 
>4 >6 >6 
Return of the ST segment on ECG to the isoline, hrs >36 >36 >36 
Treatment 
(Prehospital Care and Initial Management) 
• All patients should be managed as if the pain is ischemic in origin, 
unless clear evidence to the contrary is established. 
• Specific care includes intravenous access; supplemental oxygen; 
pulse oximetry; immediate administration of aspirin; nitroglycerin 
for active chest pain; telemetry and prehospital ECG, if available. 
• Additional objectives include adequate analgesia (generally 
achieved with morphine); pharmacologic reduction of excessive 
sympathoadrenal and vagal stimulation; treatment of ventricular 
arrhythmias; support of cardiac output, and respiration. 
• Prehospital fibrinolytic therapy by the administration of tissue-
type plasminogen activator , aspirin, and heparin may be given by 
paramedics, as guided by electrocardiographic findings, within 90 
minutes of the onset of symptoms. 
 
 
 emedicine.medscape.com/article/155919-treatment#d5 
Treatment 
(Emergency Department Care and In-Hospital 
Management) 
• Triage and evaluation: because ACS is a spectrum of conditions, 
initial evaluation to establish a working diagnosis is crucial, as this 
will dictate management owing to some differences in 
management steps and timelines for each component of the ACS 
spectrum. 
• Initial management:  restoration of the balance between oxygen 
supply and demand to prevent further ischemia; pain relief, 
prevention and treatment of complications. 
 
 emedicine.medscape.com/article/155919-treatment#d5 
Treatment 
(Suggested Algorithm for Triaging Patients with Chest Pain) 
 emedicine.medscape.com/article/1910735-overview#showall 
Treatment 
(Presumed ACS  and NSTEMI) 
• The accepted management is empirical treatment with aspirin, 
a second platelet inhibitor such as clopidogrel, and heparin 
(usually a low-molecular weight heparin such as enoxaparin), 
with intravenous glyceryl trinitrate and opioids if the pain 
persists. 
• A blood test is generally performed for cardiac troponins twelve 
hours after onset of the pain and if this is positive, coronary 
angiography is typically performed on an urgent basis.   
• If there is no evidence of ST segment elevation on the 
electrocardiogram, delaying urgent angioplasty until the next 
morning is not inferior to doing so immediately.   
/en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms 
Treatment 
(STEMI) 
• If the ECG confirms changes suggestive of MI, thrombolytics 
may be administered or primary coronary angioplasty may 
be performed.  
• The time frame for door-to-needle thrombolytic 
administration should be within 30 minutes, whereas the 
door-to-balloon Percutaneous Coronary Intervention (PCI) 
time should be less than 90 minutes. 
/en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms 
Treatment 
(Absolute and Relative Contraindications to 
Fibrinolytic Therapy) 
 emedicine.medscape.com/article/155919-treatment#d25 
Absolute Contraindications Relative Contraindications 
Prior intracranial hemorrhage 
Structural cerebral vascular lesion 
Intracranial neoplasm 
Ischemic stroke within the past 3 months 
(except for acute stroke within 4.5 hours) 
Suspected aortic dissection 
Active bleeding or bleeding diathesis 
(excluding menses) 
Significant closed-head or facial trauma within 
3 months 
Intracranial or intraspinal surgery within 2 
months 
Severe uncontrolled hypertension 
(unresponsive to emergency therapy) 
For streptokinase (no longer marketed in the 
US): Prior treatment within previous 6 months 
Chronic, severe, poorly controlled 
hypertension 
Systolic pressure >180 mm Hg or diastolic 
pressure >110 mm Hg 
History of prior ischemic stroke >3 months 
Dementia 
Intracranial pathology 
Traumatic or prolonged CPR (>10 minutes) 
Recent (within 2-4 weeks) internal bleeding 
Noncompressible vascular punctures 
Pregnancy 
Active peptic ulcer disease 
Current use of anticoagulants 
For streptokinase: prior exposure (>5 days 
previously) or prior allergic reaction to these 
agents 
CPR = cardiopulmonary resuscitation 
Treatment 
(Absolute and Relative Contraindications to 
Fibrinolytic Therapy) 
 emedicine.medscape.com/article/155919-treatment#d25 
Fibrinolytic Agent Dose Fibrin 
Specificity 
Antigenic Patency Rate 
Streptokinase (no 
longer marketed in 
the US) 
1.5 million units IV given over 30–60 min No Yes 60%–68% 
Tenecteplase 
 
 
 
(TNK-tPA) 
30 mg for weight <60 kg 
35 mg for 60–69 kg 
40 mg for 70–79 kg 
45 mg for 80–89 kg 
50 mg for >90 kg 
++++ No 85% 
Reteplase (rPA) 10-U IV boluses given 30 min apart ++ No 84% 
Alteplase (tPA) Bolus 15 mg followed by infusion 0.75 mg/kg 
for 30 min (maximum 50 mg), then 0.5 mg/kg 
(maximum 35 mg) over the next 60 min; total 
dose not to exceed 100 mg. 
++ No 73%-84% 
IV = intravenous; rPA = recombinant human tissue plasminogen activator; STEMI = ST-elevation myocardial 
infarction; tPA = tissue plasminogen activator; US = United States of America. 
Treatment 
(Cardioprotective Medications) 
• Inhibitors of the renin-angiotensin-aldosterone (RAA) system 
• Beta blockers 
• Statins 
 
en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms 
Treatment 
(Troponin in MI reperfusion) 
dpmls89.wordpress.com/2012/09/09/a-quick-review-of-troponins/ 
Treatment 
(Components of Delay in ACS and Ideal Time Intervals 
for Intervention) 
eurheartj.oxfordjournals.org/content/33/20/2569#T3 
Treatment 
(Revascularization) 
• Percutaneous 
coronary 
intervention 
• Coronary artery 
bypass surgery 
• Revascularization 
vs. medical 
therapy 
hemodinamiadelsur.com.ar/journals/journal_130.asp 
Treatment 
(Stress’ Optimization) 
• Upon hyperreactive distress and accelerated necrotic 
processes, our aim is to decrease the former and to retard the 
latter, using beta blockaders and anti-inflammatory drugs 
administered enterally and/or parenterally. 
• Hyporeactive distress and retarded necrotic processes require 
the prescription of alpha -and beta- adrenostimulators, 
bacterial and leukocytic pyrogens, leukopoiesis stimulants, 
using several ways of administration. 
• Upon intermittent distress, the attitude should be even more 
careful to prevent wave recurrence of necrotic processes. 
meteopathy.com/zdorovye-i-bolezn/my-myocardial-infarction-phylosophy/3/ 
Lifestyle Modifications and Cardiac 
Rehabilitation  
• Extensive patient education that includes providing easily 
understood and culturally sensitive written and verbal 
instructions about symptoms of ACS, as well as how and when 
to seek emergency care, in addition to providing instructions 
about medication types, purposes, doses, frequency, and side 
effects. 
• Dietary changes that adopt a low-fat and low-salt diet with 
dietary counseling, smoking cessation, up-to-date vaccination, 
and an increase in physical activity and exercise. 
• Aerobic exercise training within a cardiac rehabilitation 
programs, with the need for an evaluation of both exercise 
capacity and exercise-associated risk. 
emedicine.medscape.com/article/155919-treatment#d7 
Prognosis  
• Six-month mortality rates in the Global Registry of Acute 
Coronary Events (GRACE) were 13% for patients with NSTEMI 
ACS and 8% for those with unstable angina. 
• The prognosis varies greatly depending on a person's health, 
the extent of the heart damage, and the treatment given. 
 emedicine.medscape.com/article/1910735-overview#a6 
Prophylaxis 
• Lifestyle recommendations include the adoption of 
a Mediterranean-type diet, maintaining alcohol intake within 
recommended limits, exercising to the point of mild 
breathlessness for 20–30 minutes every day, stopping 
smoking, and trying to achieve a healthy weight. 
• Exercise is both safe and effective even if people have had 
stents or heart failure. 
• People are usually started on several long-term medications: 
aspirin, warfarin, beta blockers, ACE inhibitors, angiotensin II 
receptor antagonist, statins,   aldosterone antagonists. 
• Previous studies suggested a benefit from omega-3 fatty 
acid supplementation but this has not been confirmed. 
en.wikipedia.org/wiki/Myocardial_infarction 
Abbreviations  
• ACE - angiotensin converting 
enzyme  
• ACS - acute coronary 
syndrome 
• ALT - alanine 
aminotransferase 
• ECG – electrocardiography 
• ICD - International 
Classification of Diseases 
• LDH - lactate dehydrogenase 
• NQMI non-Q-wave 
myocardial infarction 
 
 
 
 
• NSTEMI - non–ST-segment 
elevation myocardial 
infarction  
• MI – acute myocardial 
infarction  
• MVO2 - myocardial oxygen 
consumption  
• STEMI - ST-segment 
elevation myocardial 
infarction 
• QMI Q-wave myocardial 
infarction 
Diagnostic and treatment guidelines 
Europe 
• 2015 ESC Guidelines for the management of acute coronary 
syndromes in patients presenting without persistent ST-
segment elevation  
• 2014 ESC/EACTS Guidelines on myocardial revascularization  
• ESC Guidelines for the management of acute myocardial 
infarction in patients presenting with ST-segment elevation  
North America 
• 2014 AHA/ACC Guideline for the Management of Patients 
With Non–ST-Elevation Acute Coronary Syndromes 
• Recommendations for best-practice STEMI management in 
Ontario 
 
 
 
